A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus

Khoshnood, S. and Heidary, M. and Asadi, A. and Soleimani, S. and Motahar, M. and Savari, M. and Saki, M. and Abdi, M. (2019) A review on mechanism of action, resistance, synergism, and clinical implications of mupirocin against Staphylococcus aureus. Biomedicine and Pharmacotherapy, 109. pp. 1809-1818.

Preview

Text A-review-on-mechanism-of-action-resistance-synergism-and-clinical-implications-of-mupirocin-against-Staphylococcus-aureus2019Biomedicine-and-Pharmacotherapy.pdf Download (4MB) | Preview

Abstract

Mupirocin (MUP), bactroban, or pseudomonic acid is a natural crotonic acid derivative drug extracted from Pseudomonas fluorescens which is produced by modular polyketide synthases. This antibiotic has a unique chemical structure and mechanism of action. It is a mixture of A�D pseudomonic acids and inhibits protein synthesis through binding to bacterial isoleucyl-tRNA synthetase. MUP is often prescribed to prevent skin and soft tissue infections caused by S. aureus isolates and where the MRSA isolates are epidemic, MUP may be used as a choice drug for nasal decolonization. It is also used for prevention of recurring infections and control the outbreaks. The emergence of MUP resistance has been increasing particularly among methicillin-resistant Staphylococcus aureus (MRSA) isolates in many parts of the world and such resistance is often related with MUP widespread uses. Although both low-level and high-level MUP resistance were reported among MRSA isolates, the rate of resistance is different in various geographic areas. In this review, we will report the global prevalence of MUP resistance, discuss synergism and mechanism of action of MUP, and provide new insights into the clinical use of this antibiotic. © 2018 Elsevier Masson SAS

Actions (login required)

View Item